<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317967</url>
  </required_header>
  <id_info>
    <org_study_id>1-Sheldon</org_study_id>
    <nct_id>NCT00317967</nct_id>
  </id_info>
  <brief_title>Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart</brief_title>
  <official_title>Statin Induced Regression of Cardiomyopathy Trial - SirCat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a drug called atorvastatin will reduce the size
      and stiffness of the muscle in the left ventricle of the heart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertrophic cardiomyopathy (HCM) is a primary disorder of the heart characterized by a
      thickened, fibrotic myocardium, with or without a dynamic left ventricular outflow tract
      gradient. It is a common heritable cardiovascular disease, with a population prevalence of
      0.1% to 0.2%. Symptoms of congestive heart failure are extremely common in patients with HCM.
      Progression to disabling and debilitating symptoms [New York Heart Association (NYHA) class
      III and IV] is relatively common, occurring in 15% to 20% of unselected populations. The rate
      of progression to NYHA class III or IV or death from heart failure or stroke is high, with a
      relative risk 2.7. Management of symptoms can be very challenging, involve multiple
      medications, and 5% of patients may develop drug refractory heart failure, requiring invasive
      intervention. HCM is the most common cause of sudden death among young competitive athletes.
      Ventricular tachyarrhythmias appear to be the primary mechanism; however, other arrhythmias
      involved include asystole, rapid atrial fibrillation, and electrical mechanical dissociation.
      Patients may develop progressive myocardial wall thinning, a reduction in systolic
      performance, and an increase in left ventricular dimensions. Progressive wall thinning may be
      especially common in patients with initially severe hypertrophy. There is no cure for this
      condition. There is now evidence from both animal and human studies of a treatment that
      promises to reverse hypertrophy - HMG CoA reductase inhibitors. Clearly, studies of
      treatments that might cause regression of hypertrophy are timely and important.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left ventricular mass at 12 months from baseline</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>a decrease in maximal ventricular wall cross sectional width</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a decrease in the incidence of nonsustained ventricular tachycardia</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a decrease in T-wave alternans</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a decrease in the volume of dense myocardial fibrosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parameters of diastolic function</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>80 mg pills daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>80 mg pills daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and over with HCM in the absence of another cardiac or systemic disease
             capable of producing a prespecified wall thickening

        Exclusion Criteria:

          -  Required use of statin therapy or intolerance

          -  A clinical diagnosis of hypertension

          -  Indication for statin therapy for primary or secondary prevention of coronary artery
             disease

          -  Current or anticipated indication in â‰¤ 1 year for implantable cardioverter
             defibrillators or other metallic devices preventing cardiac magnetic resonance imaging
             (MRI).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S. Sheldon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary, Faculty of Medicine</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2006</study_first_submitted>
  <study_first_submitted_qc>April 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2006</study_first_posted>
  <last_update_submitted>December 5, 2013</last_update_submitted>
  <last_update_submitted_qc>December 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Bob Sheldon</investigator_full_name>
    <investigator_title>Professor of Cardiac Sciences, Medicine and Medical Genetics</investigator_title>
  </responsible_party>
  <keyword>Hypertrophic cardiomyopathy</keyword>
  <keyword>Statin therapy</keyword>
  <keyword>Regression</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Arrhythmias</keyword>
  <keyword>Sudden cardiac death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

